Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Standard risk factors stratify already high-risk diabetic patients

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Hypertension, antihypertensive medications may increase risk of psoriasis in women

Hypertension, antihypertensive medications may increase risk of psoriasis in women

Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis. [More]
Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives. [More]
Herbal supplement can become dangerous when taken with prescribed drugs

Herbal supplement can become dangerous when taken with prescribed drugs

St. John's wort, the leading complementary and alternative treatment for depression in the United States, can be dangerous when taken with many commonly prescribed drugs, according to a study by researchers at Wake Forest Baptist Medical Center. [More]
Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence. [More]
Complete analysis of regenerative medicine market

Complete analysis of regenerative medicine market

According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). [More]
Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT. [More]
Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China. [More]
Arthritis drug promotes hair growth in hairless man

Arthritis drug promotes hair growth in hairless man

A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University. [More]
Researchers find shared genetic link in autoimmune response among PV patients

Researchers find shared genetic link in autoimmune response among PV patients

Autoimmune disease occurs when the body's own natural defense system rebels against itself. One example is pemphigus vulgaris (PV), a blistering skin disease in which autoantibodies attack desmoglein 3 (Dsg3), the protein that binds together skin cells. [More]
Ambulatory blood pressure risk is age dependent

Ambulatory blood pressure risk is age dependent

The risk associated with raised ambulatory blood pressure is modified by a patient’s age, research shows. [More]
Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma. [More]
Auxilium and Prasco introduce authorized generic version of Testim

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel). [More]
Haemodynamic exercise variables “important” for PAH prognostication

Haemodynamic exercise variables “important” for PAH prognostication

Exercise haemodynamic variables, measured shortly after diagnosis, correlate with exercise capacity and predict survival in patients with pulmonary arterial hypertension, study findings indicate. [More]
‘Real-world’ ambrisentan data unveiled

‘Real-world’ ambrisentan data unveiled

The use of and outcomes with ambrisentan in clinical practice are different to those in clinical trials, reflecting different patient characteristics in the “real world”, say researchers. [More]

ClarityMD effective in clearing acne without irritation

Envy Medical, Inc., a leader in professional skincare products and services, is excited to announce the publication of a new study in the June issue of the Journal of Drugs in Dermatology (JDD) proving the superior efficacy of its highly innovative acne system – ClarityMD. [More]
Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. [More]
Prevalence of pulmonary arterial hypertension characterised in CHD patients

Prevalence of pulmonary arterial hypertension characterised in CHD patients

Pulmonary arterial hypertension affects just over 3% of individuals with congenital heart disease, reveal nationwide data from the Netherlands. [More]
Cardiac biomarkers aid microvascular risk prediction in diabetics

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers. [More]